Literature DB >> 1317349

Interleukin-6 regulates the cytotoxic effect of tumour necrosis factor on U937 cells.

J A Cairns1, G R Guy, Y H Tan.   

Abstract

In this study, we demonstrate that low but not high concentrations of interleukin-6 (IL-6) potentiate the cytotoxic effect of tumour necrosis factor-alpha (TNF-alpha) on U937 cells, in a dose-dependent manner. Killing of U937 cells by 100 U/ml of TNF-alpha, was maximally potentiated by 50 U/ml of IL-6. No potentiation of cell killing was observed when the concentration of IL-6 was increased to 4000 U/ml. At a concentration of 50 U/ml, IL-6 up-regulated TNF receptor expression but no change in TNF receptor number was observed when the concentration of IL-6 was increased to 4000 U/ml. Low concentrations of IL-6 can also induce sub-cytotoxic doses of TNF-alpha (0.1 and 0.33 U/ml) to kill U937 cells. Up-regulation of TNF receptors by IL-6 is dependent on de novo protein synthesis since receptor induction is abolished in the presence of cycloheximide. Taken together the data suggest that the potentiation of cell killing observed by a combination of these lymphokines is mediated in part by IL-6-induced changes in TNF receptor expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317349      PMCID: PMC1384848     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans.

Authors:  N Sheron; J N Lau; J Hofmann; R Williams; G J Alexander
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

4.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.

Authors:  D Aderka; J M Le; J Vilcek
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

5.  Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

Authors:  H F Starnes; M K Pearce; A Tewari; J H Yim; J C Zou; J S Abrams
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

6.  Interleukin-6 enhances the expression of tumor necrosis factor receptors on hepatoma cells and hepatocytes.

Authors:  S Van Bladel; C Libert; W Fiers
Journal:  Cytokine       Date:  1991-03       Impact factor: 3.861

7.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

8.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

Authors:  T Hirano; T Taga; N Nakano; K Yasukawa; S Kashiwamura; K Shimizu; K Nakajima; K H Pyun; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.

Authors:  S Yonehara; A Ishii; M Yonehara
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

10.  Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma.

Authors:  P Brouckaert; D R Spriggs; G Demetri; D W Kufe; W Fiers
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  5 in total

1.  A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon.

Authors:  M B Welborn; K Van Zee; P D Edwards; J H Pruitt; A Kaibara; J N Vauthey; M Rogy; W L Castleman; S F Lowry; J S Kenney; D Stüber; U Ettlin; B Wipf; H Loetscher; E M Copeland; W Lesslauer; L L Moldawer
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

2.  Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6.

Authors:  M Kawada; M Ishizuka; T Takeuchi
Journal:  Jpn J Cancer Res       Date:  1999-05

3.  Mastoparan, a Peptide Toxin from Wasp Venom Conjugated Fluvastatin Nanocomplex for Suppression of Lung Cancer Cell Growth.

Authors:  Nabil A Alhakamy; Osama A A Ahmed; Shadab Md; Usama A Fahmy
Journal:  Polymers (Basel)       Date:  2021-12-02       Impact factor: 4.329

4.  T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6.

Authors:  H Mizuhara; E O'Neill; N Seki; T Ogawa; C Kusunoki; K Otsuka; S Satoh; M Niwa; H Senoh; H Fujiwara
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

5.  Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.

Authors:  T van der Poll; M Levi; C E Hack; H ten Cate; S J van Deventer; A J Eerenberg; E R de Groot; J Jansen; H Gallati; H R Büller
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.